Loading…
No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months
Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated. The cohort of PD patients attending our center which tackled the challenge o...
Saved in:
| Published in: | BMC nephrology 2017-08, Vol.18 (1), p.278-278, Article 278 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73 |
| container_end_page | 278 |
| container_issue | 1 |
| container_start_page | 278 |
| container_title | BMC nephrology |
| container_volume | 18 |
| creator | Pagniez, Dominique Duhamel, Alain Boulanger, Eric Lessore de Sainte Foy, Celia Beuscart, Jean-Baptiste |
| description | Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated.
The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D
/D
ratios over time computed for each individual, and (2) a linear mixed model.
In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D
/D
ratios was found to be significantly positive (Student's test, p |
| doi_str_mv | 10.1186/s12882-017-0690-7 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6a1fa22302e6408fac712aadbac3510c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A509118791</galeid><doaj_id>oai_doaj_org_article_6a1fa22302e6408fac712aadbac3510c</doaj_id><sourcerecordid>A509118791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73</originalsourceid><addsrcrecordid>eNptks1u1DAUhSMEoqXwAGxQJDYsSPFPbCcbpFEFtNIINrC2bhx7xqMkHmyn1Wx4dm6YUtoKeRHL_s5xfHyK4jUl55Q28kOirGlYRaiqiGxJpZ4Up7RWtGJctk_vzU-KFyntCIJNTZ4XJygTrSTytPj1NZR-MtFCsjgp0wjDUKUwzNmWOcKU9iHmZWdvo89hsjCUvYfhkHwq95C9nXJC0kK2fXnj8zbMudweEEfam3IzzCaguQuxdN7lQ-XCHMsxTHmbXhbPHAzJvrr9nhU_Pn_6fnFZrb99ubpYrSsjWpWrtpZC8qbrFDOKgzAUrOtbRVpeO9FDUyvHerCsc7yuqVSCmq6TtaQMGHSKnxVXR98-wE7vox8hHnQAr_8shLjRELM3g9USqAPGOGFW1qRxYBS6QN-B4YISg14fj177uRttbzCACMMD04c7k9_qTbjWQjSEM4IG748G20eyy9Va-ynZOGrCSEOoUNcU8Xe358Xwc7Yp69EnY4cBJhvmpGnLJRUtJxzRt4_QHWY9YbILhXEQTsg_agN4Xz-5gL9pFlO9EqTFaql2Ofb8PxSO3o7eYBGcx_UHAnoUmBhSitbd3Y0SvfRVH_uqsYZ66ate3uXN_SzvFH8Lyn8DbFvnLw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1934610300</pqid></control><display><type>article</type><title>No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Pagniez, Dominique ; Duhamel, Alain ; Boulanger, Eric ; Lessore de Sainte Foy, Celia ; Beuscart, Jean-Baptiste</creator><creatorcontrib>Pagniez, Dominique ; Duhamel, Alain ; Boulanger, Eric ; Lessore de Sainte Foy, Celia ; Beuscart, Jean-Baptiste</creatorcontrib><description>Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated.
The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D
/D
ratios over time computed for each individual, and (2) a linear mixed model.
In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D
/D
ratios was found to be significantly positive (Student's test, p < .001) and the results of the mixed model reflected a similar significant increase for D
/D
ratios over time. These results reflected a significant decrease of small-solute transport.
In this large series, minimizing the use of hypertonic glucose solutions was associated in patients on long term PD with an overall decrease of small-solute transport within 54 months, despite a high rate of peritoneal infection.</description><identifier>ISSN: 1471-2369</identifier><identifier>EISSN: 1471-2369</identifier><identifier>DOI: 10.1186/s12882-017-0690-7</identifier><identifier>PMID: 28859606</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Analysis ; Biological Transport - drug effects ; Biological Transport - physiology ; Cohort Studies ; Complications and side effects ; Continuous ambulatory peritoneal dialysis ; Dextrose ; Female ; Follow-Up Studies ; Glucose ; Glucose exposure ; Glucose Solution, Hypertonic - administration & dosage ; Glucose sparing ; Human health and pathology ; Humans ; Infection ; Infections ; Kidney Failure, Chronic - diagnosis ; Kidney Failure, Chronic - metabolism ; Kidney Failure, Chronic - therapy ; Life Sciences ; Male ; Metabolism ; Middle Aged ; Nephrology ; Patient outcomes ; Patients ; Peritoneal dialysis ; Peritoneal Dialysis - methods ; Peritoneal Dialysis - trends ; Peritoneal equilibration test ; Peritoneum ; Permeability ; Risk factors ; Small-solute transport ; Time Factors ; Transplants & implants ; Treatment Outcome ; Urology and Nephrology</subject><ispartof>BMC nephrology, 2017-08, Vol.18 (1), p.278-278, Article 278</ispartof><rights>COPYRIGHT 2017 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2017</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>The Author(s). 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73</citedby><cites>FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73</cites><orcidid>0000-0002-0734-8371</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580320/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1934610300?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28859606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-02080157$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pagniez, Dominique</creatorcontrib><creatorcontrib>Duhamel, Alain</creatorcontrib><creatorcontrib>Boulanger, Eric</creatorcontrib><creatorcontrib>Lessore de Sainte Foy, Celia</creatorcontrib><creatorcontrib>Beuscart, Jean-Baptiste</creatorcontrib><title>No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months</title><title>BMC nephrology</title><addtitle>BMC Nephrol</addtitle><description>Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated.
The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D
/D
ratios over time computed for each individual, and (2) a linear mixed model.
In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D
/D
ratios was found to be significantly positive (Student's test, p < .001) and the results of the mixed model reflected a similar significant increase for D
/D
ratios over time. These results reflected a significant decrease of small-solute transport.
In this large series, minimizing the use of hypertonic glucose solutions was associated in patients on long term PD with an overall decrease of small-solute transport within 54 months, despite a high rate of peritoneal infection.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis</subject><subject>Biological Transport - drug effects</subject><subject>Biological Transport - physiology</subject><subject>Cohort Studies</subject><subject>Complications and side effects</subject><subject>Continuous ambulatory peritoneal dialysis</subject><subject>Dextrose</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Glucose exposure</subject><subject>Glucose Solution, Hypertonic - administration & dosage</subject><subject>Glucose sparing</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Kidney Failure, Chronic - diagnosis</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Peritoneal dialysis</subject><subject>Peritoneal Dialysis - methods</subject><subject>Peritoneal Dialysis - trends</subject><subject>Peritoneal equilibration test</subject><subject>Peritoneum</subject><subject>Permeability</subject><subject>Risk factors</subject><subject>Small-solute transport</subject><subject>Time Factors</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Urology and Nephrology</subject><issn>1471-2369</issn><issn>1471-2369</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1u1DAUhSMEoqXwAGxQJDYsSPFPbCcbpFEFtNIINrC2bhx7xqMkHmyn1Wx4dm6YUtoKeRHL_s5xfHyK4jUl55Q28kOirGlYRaiqiGxJpZ4Up7RWtGJctk_vzU-KFyntCIJNTZ4XJygTrSTytPj1NZR-MtFCsjgp0wjDUKUwzNmWOcKU9iHmZWdvo89hsjCUvYfhkHwq95C9nXJC0kK2fXnj8zbMudweEEfam3IzzCaguQuxdN7lQ-XCHMsxTHmbXhbPHAzJvrr9nhU_Pn_6fnFZrb99ubpYrSsjWpWrtpZC8qbrFDOKgzAUrOtbRVpeO9FDUyvHerCsc7yuqVSCmq6TtaQMGHSKnxVXR98-wE7vox8hHnQAr_8shLjRELM3g9USqAPGOGFW1qRxYBS6QN-B4YISg14fj177uRttbzCACMMD04c7k9_qTbjWQjSEM4IG748G20eyy9Va-ynZOGrCSEOoUNcU8Xe358Xwc7Yp69EnY4cBJhvmpGnLJRUtJxzRt4_QHWY9YbILhXEQTsg_agN4Xz-5gL9pFlO9EqTFaql2Ofb8PxSO3o7eYBGcx_UHAnoUmBhSitbd3Y0SvfRVH_uqsYZ66ate3uXN_SzvFH8Lyn8DbFvnLw</recordid><startdate>20170831</startdate><enddate>20170831</enddate><creator>Pagniez, Dominique</creator><creator>Duhamel, Alain</creator><creator>Boulanger, Eric</creator><creator>Lessore de Sainte Foy, Celia</creator><creator>Beuscart, Jean-Baptiste</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0734-8371</orcidid></search><sort><creationdate>20170831</creationdate><title>No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months</title><author>Pagniez, Dominique ; Duhamel, Alain ; Boulanger, Eric ; Lessore de Sainte Foy, Celia ; Beuscart, Jean-Baptiste</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis</topic><topic>Biological Transport - drug effects</topic><topic>Biological Transport - physiology</topic><topic>Cohort Studies</topic><topic>Complications and side effects</topic><topic>Continuous ambulatory peritoneal dialysis</topic><topic>Dextrose</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Glucose exposure</topic><topic>Glucose Solution, Hypertonic - administration & dosage</topic><topic>Glucose sparing</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Kidney Failure, Chronic - diagnosis</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Peritoneal dialysis</topic><topic>Peritoneal Dialysis - methods</topic><topic>Peritoneal Dialysis - trends</topic><topic>Peritoneal equilibration test</topic><topic>Peritoneum</topic><topic>Permeability</topic><topic>Risk factors</topic><topic>Small-solute transport</topic><topic>Time Factors</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Urology and Nephrology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pagniez, Dominique</creatorcontrib><creatorcontrib>Duhamel, Alain</creatorcontrib><creatorcontrib>Boulanger, Eric</creatorcontrib><creatorcontrib>Lessore de Sainte Foy, Celia</creatorcontrib><creatorcontrib>Beuscart, Jean-Baptiste</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pagniez, Dominique</au><au>Duhamel, Alain</au><au>Boulanger, Eric</au><au>Lessore de Sainte Foy, Celia</au><au>Beuscart, Jean-Baptiste</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months</atitle><jtitle>BMC nephrology</jtitle><addtitle>BMC Nephrol</addtitle><date>2017-08-31</date><risdate>2017</risdate><volume>18</volume><issue>1</issue><spage>278</spage><epage>278</epage><pages>278-278</pages><artnum>278</artnum><issn>1471-2369</issn><eissn>1471-2369</eissn><abstract>Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated.
The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D
/D
ratios over time computed for each individual, and (2) a linear mixed model.
In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D
/D
ratios was found to be significantly positive (Student's test, p < .001) and the results of the mixed model reflected a similar significant increase for D
/D
ratios over time. These results reflected a significant decrease of small-solute transport.
In this large series, minimizing the use of hypertonic glucose solutions was associated in patients on long term PD with an overall decrease of small-solute transport within 54 months, despite a high rate of peritoneal infection.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>28859606</pmid><doi>10.1186/s12882-017-0690-7</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0734-8371</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2369 |
| ispartof | BMC nephrology, 2017-08, Vol.18 (1), p.278-278, Article 278 |
| issn | 1471-2369 1471-2369 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_6a1fa22302e6408fac712aadbac3510c |
| source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
| subjects | Adult Aged Analysis Biological Transport - drug effects Biological Transport - physiology Cohort Studies Complications and side effects Continuous ambulatory peritoneal dialysis Dextrose Female Follow-Up Studies Glucose Glucose exposure Glucose Solution, Hypertonic - administration & dosage Glucose sparing Human health and pathology Humans Infection Infections Kidney Failure, Chronic - diagnosis Kidney Failure, Chronic - metabolism Kidney Failure, Chronic - therapy Life Sciences Male Metabolism Middle Aged Nephrology Patient outcomes Patients Peritoneal dialysis Peritoneal Dialysis - methods Peritoneal Dialysis - trends Peritoneal equilibration test Peritoneum Permeability Risk factors Small-solute transport Time Factors Transplants & implants Treatment Outcome Urology and Nephrology |
| title | No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A24%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20increase%20in%20small-solute%20transport%20in%20peritoneal%20dialysis%20patients%20treated%20without%20hypertonic%20glucose%20for%20fifty-four%20months&rft.jtitle=BMC%20nephrology&rft.au=Pagniez,%20Dominique&rft.date=2017-08-31&rft.volume=18&rft.issue=1&rft.spage=278&rft.epage=278&rft.pages=278-278&rft.artnum=278&rft.issn=1471-2369&rft.eissn=1471-2369&rft_id=info:doi/10.1186/s12882-017-0690-7&rft_dat=%3Cgale_doaj_%3EA509118791%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c597t-9465638bb72c73a5c1aefd970934f5da847f2dae2bf34416751cbb64612a2ab73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1934610300&rft_id=info:pmid/28859606&rft_galeid=A509118791&rfr_iscdi=true |